Comprehensive therapy最新文献_第2页

Physiology of an Eating Disorder 饮食失调的生理学

Comprehensive therapy Pub Date : 2017-08-10 DOI: 10.1201/9781315153124-3

Vicki Berkus

引用次数: 0

Highly expressed lncRNA CRNDE promotes cell proliferation through Wnt/β-catenin signaling in renal cell carcinoma. 高表达的lncRNA CRNDE通过Wnt/β-catenin信号在肾细胞癌中促进细胞增殖。

Comprehensive therapy Pub Date : 2016-12-01 Epub Date: 2016-10-06 DOI: 10.1007/s13277-016-5440-0

Kun Shao, Tianming Shi, Yang Yang, Xianghui Wang, Da Xu, Peijun Zhou

{"title":"Highly expressed lncRNA CRNDE promotes cell proliferation through Wnt/β-catenin signaling in renal cell carcinoma.","authors":"Kun Shao, Tianming Shi, Yang Yang, Xianghui Wang, Da Xu, Peijun Zhou","doi":"10.1007/s13277-016-5440-0","DOIUrl":"10.1007/s13277-016-5440-0","url":null,"abstract":"Recently, numerous studies revealed that long non-coding RNAs (lncRNAs) play complex roles in the field of tumor biology, while the functions of lncRNA in renal cell carcinoma (RCC) remain largely unknown. In the current study, we retrieved Oncomine database and found a lncRNA colorectal neoplasia differentially expressed (CRNDE) which is highly expressed in different cohorts of RCC patients; this clue reminds us that CRNDE might exert its functions in RCC tumorigenesis. We then detected the level of CRNDE in fresh RCC tissues and found that CRNDE is significantly up-regulated compared with adjacent tissues. Furthermore, both loss and gain function assays revealed that CRNDE promotes RCC cell proliferation and growth both in vitro and in vivo.In addition, we found that CRNDE regulates the cell cycle transition from G0/G1 stage to S stage and modulates the expression of CCND1 and CCNE1. Moreover, we further illustrated that CRNDE activates Wnt/β-catenin signaling in RCC cell lines. Taken together, in the current study, we found that lncRNA CRNDE is highly expressed in RCC malignant tissues and the heightened CRNDE robustly promotes RCC cell proliferation through activating Wnt/β-catenin signaling; our findings enlarge our knowledge in the molecular pathology of RCC tumorigenesis.","PeriodicalId":75729,"journal":{"name":"Comprehensive therapy","volume":"24 3 1","pages":"15997–16004"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"53039554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastroesophageal reflux. 胃食管反流。

Comprehensive therapy Pub Date : 2016-04-30 DOI: 10.1542/9781610020190-part02-gastroesophageal

W. Wu, D. Castell

引用次数: 0

Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects. 免疫球蛋白 a 肾病的最新进展。第二部分：临床、诊断和治疗方面。

Comprehensive therapy Pub Date : 2016-01-06 DOI: 10.5527/wjn.v5.i1.6

Maurizio Salvadori, Giuseppina Rosso

{"title":"Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.","authors":"Maurizio Salvadori, Giuseppina Rosso","doi":"10.5527/wjn.v5.i1.6","DOIUrl":"10.5527/wjn.v5.i1.6","url":null,"abstract":"Immunoglobulin A nephropathy (IgAN) is characterized by different clinical manifestations and by long-term different outcomes. Major problem for the physicians is to understanding which patients are at risk of a disease evolution and to prescribe the right therapy to the right patients. Indeed, in addition to patients with a stable disease with no trend to evolution or even with a spontaneous recovery, patients with an active disease and patients with a rapidly evolving glomerulonephritis are described. Several histopathological, biological and clinical markers have been described and are currently used to a better understanding of patients at risk, to suggest the right therapy and to monitor the therapy effect and the IgAN evolution over time. The clinical markers are the most reliable and allow to divide the IgAN patients into three categories: The low risk patients, the intermediate risk patients and the high risk patients. Accordingly, the therapeutic measures range from no therapy with the only need of repeated controls, to supportive therapy eventually associated with low dose immunosuppression, to immunosuppressive treatment in the attempt to avoid the evolution to end stage renal disease. However the current evidence about the different therapies is still matter of discussion. New drugs are in the pipeline and are described. They are object of randomized controlled trials, but studies with a number of patients adequately powered and with a long follow up are needed to evaluate efficacy and safety of these new drugs. ","PeriodicalId":75729,"journal":{"name":"Comprehensive therapy","volume":"30 1","pages":"6-19"},"PeriodicalIF":0.0,"publicationDate":"2016-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74326211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chapter 3 – Pulmonary Embolism 第三章-肺栓塞

Comprehensive therapy Pub Date : 2016-01-01 DOI: 10.1016/B978-0-12-803376-0.00003-4

P. Manu, C. Hohman, James F. Barrecchia, M. Shulman

引用次数: 0

Electrolyte and Acid-Base Disturbances in Diabetes Mellitus. 糖尿病患者的电解质和酸碱紊乱。

Comprehensive therapy Pub Date : 2015-12-17 DOI: 10.1056/NEJMc1511638

Mark L. Graber

引用次数: 1

Rocky mountain spotted fever. 落基山斑疹热。

Comprehensive therapy Pub Date : 2015-05-01 DOI: 10.1542/9781581109276-rocky

R. S. Marx